Skip to main content
IDWeek 2021 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
View Session ViewAttendees 45

Adult ID

Epidemiology & Infection Control

Global ID

HIV-STD-TB

Pediatric ID

Trainee

Transplant
Meet-the-Professor

64 - New TB Treatment Options

Friday, October 1, 2021
10:00 AM - 11:15 AM EDT

    Moderator(s)

  • Laila Woc-Colburn, MD

    Associate Professor
    Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine
    Decatur, GA, United States

    I do not have any relevant financial / non-financial relationships with any proprietary interests.

    • Speaker(s)

  • Susan Dorman, MD

    Professor of Medicine
    Medical University of South Carolina, SC, United States

    I do not have any relevant financial / non-financial relationships with any proprietary interests.

  • Charles Peloquin, Pharm.D.

    Professor and Director, Infectious Disease Pharmacokinetics Laboratory
    Pharmacology
    University of Florida
    Gainesville, FL, United States

    I do not have any relevant financial / non-financial relationships with any proprietary interests.

Participants should be aware of the following financial/non-financial relationships:
Laila Woc-Colburn, MD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Susan Dorman, MD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Charles A. Peloquin, Pharm.D.: I do not have any relevant financial / non-financial relationships with any proprietary interests.

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
ACPE Credits: ACPE 1.25 Knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-0000-21-001-H01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:
  • review new treatment options that are available for managing patients with drug intolerance or drug resistant TB
  • discuss how laboratory testing impacts treatment decisions and the need for access to molecular tests, including next generation sequencing
  • learn about therapeutic drug monitoring (TDM) and how it can be used in conjunction with minimal inhibitory concentration (MIC) testing to tailor patient treatment

Presentations:

  • Case Presentations That Highlight the Use of New TB Regimens for Patients Intolerant of Standard Treatments

    Speaker: Susan Dorman, MD – Medical University of South Carolina

  • Use of Therapeutic Drug Monitoring for Individualized TB Treatment

    Speaker: Charles A. Peloquin, Pharm.D. – University of Florida